biostudies-literatureVila-Corcoles AInstituto de Salud Carlos IIIe041577https://www.ebi.ac.uk/biostudies/studies/S-EPMC7733229biostudies-literatureUnknown10(12)<h4>Objective</h4>To investigate possible relationships between pre-existing medical conditions (including common comorbidities and chronic medications) and risk for suffering COVID-19 disease in middle-aged and older adults.<h4>Design</h4>Population-based retrospective cohort study.<h4>Setting</h4>Twelve primary care centres (PCCs) in Tarragona (Spain).<h4>Participants</h4>79 083 people (77 676 community-dwelling and 1407 nursing-home residents), who were all individuals aged >50 years affiliated to the 12 participating PCCs.<h4>Outcomes</h4>Baseline cohort characteristics (age, sex, vaccinations, comorbidities and chronic medications) were established at study start (1st. March 2020) and primary outcome was time to COVID-19 confirmed by PCR among cohort members throughout the epidemic peBMJ openInfluence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain.PMC7733229COV20/00852Vila-Rovira AOchoa-Gondar OHospital-Guardiola Ide Diego-Cabanes CBasora-Gallisa JVila-Corcoles AGomez-Bertomeu FBejarano-Romero FSatue-Gracia EMTorrente-Fraga CfalseInfluence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain.<h4>Objective</h4>To investigate possible relationships between pre-existing medical conditions (including common comorbidities and chronic medications) and risk for suffering COVID-19 disease in middle-aged and older adults.<h4>Design</h4>Population-based retrospective cohort study.<h4>Setting</h4>Twelve primary care centres (PCCs) in Tarragona (Spain).<h4>Participants</h4>79 083 people (77 676 community-dwelling and 1407 nursing-home residents), who were all individuals aged >50 years affiliated to the 12 participating PCCs.<h4>Outcomes</h4>Baseline cohort characteristics (age, sex, vaccinations, comorbidities and chronic medications) were established at study start (1st. March 2020) and primary outcome was time to COVID-19 confirmed by PCR among cohort members throughout the epidemic pe2020-01-01T00:00:00Z2020 Dec2025-04-04T03:06:19.189Z2021-02-20T10:33:25ZS-EPMC77332293330345910.1136/bmjopen-2020-041577